RxDoctor Payments Data

David Crosby

Physician Assistant · Stratford, CTNPI 1588139604

Payments from drug & device makers

$382in general payments, 2019–2025

Across 17 payments — averaging $22.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$181
  • AstraZeneca$53
  • Biohaven Pharmaceuticals, Inc.$24
  • Nestle Healthcare Nutrition Inc.$22
  • Astellas Pharma US Inc$20
  • Vanda Pharmaceuticals Inc.$15
  • plus $66 from 5 others

What the payments were for

  • Food & beverage$382100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$382 in reported general payments places this provider in the 70th percentile of 1,795 physician assistant providers in Connecticut.

See all physician assistant providers in Connecticut

Medicare billing

Part B allowed, 2024
$25,552
Medicare patients
126
Services billed
296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate41$49,648
TrulicityDulaglutide31$32,912
EliquisApixaban29$32,037
OzempicSemaglutide27$30,122
OxycontinOxycodone Hcl21$26,272
JardianceEmpagliflozin13$21,812
FarxigaDapagliflozin Propanediol15$16,380
TradjentaLinagliptin17$10,554
MyrbetriqMirabegron11$9,566
Tresiba Flextouch U-100Insulin Degludec12$8,830
Breo ElliptaFluticasone/Vilanterol11$7,779
SymbicortBudesonide/Formoterol Fumarate20$4,958
Diclofenac Sodium28$4,711
Fluticasone Propionate HfaFluticasone Propionate12$4,102
Atorvastatin Calcium356$3,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$15$32,91231 claims
Novo NordiskOzempic$13$30,12227 claims
AstraZenecaFarxiga, Symbicort$53$21,33735 claims
Astellas Pharma US IncMyrbetriq$20$9,56611 claims
AbbVieSynthroid$181$1,36519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,795 physician assistant providers in Connecticut.

Other physician assistant in Stratford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →